Results 51 to 60 of about 216,439 (378)

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Blood, 2015
Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of ...
P. Valent, E. Hadzijusufovic, G. Schernthaner, D. Wolf, D. Réa, P. le Coutre   +5 more
semanticscholar   +1 more source

The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]

, 2017
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

New England Journal of Medicine, 2006
BACKGROUND Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a ...
H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'brien, B. Wassmann, C. Tanaka, P. Manley, Patricia Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J. Griffin, D. Hoelzer, M. Albitar, M. Dugan, J. Cortes, L. Alland, O. Ottmann   +18 more
semanticscholar   +1 more source

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.

Cancer Discovery, 2016
A major obstacle to curing chronic myeloid leukemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells (LSC).
M. Scott, Koorosh Korfi, P. Saffrey, L. Hopcroft, Ross Kinstrie, F. Pellicanò, Carla Guenther, P. Gallipoli, M. Cruz, Karen M. Dunn, H. Jørgensen, Jennifer E. Cassels, A. Hamilton, A. Crossan, A. Sinclair, T. Holyoake, D. Vetrie   +16 more
semanticscholar   +1 more source

Programming Idioms for Transactional Events

, 2010
Transactional events (TE) are an extension of Concurrent ML (CML), a programming model for synchronous message-passing. Prior work has focused on TE's formal semantics and its implementation.
Alastair R. Beresford, Dan Grossman, John Reppy, Kevin Donnelly, Laura Effinger-Dean, Laura Effinger-Dean, Matthew Kehrt, Michael Schmitz, Simon Gay   +8 more
core   +4 more sources

Connectionist modal logic: Representing modalities in neural networks [PDF]

, 2007
Modal logics are amongst the most successful applied logical systems. Neural networks were proved to be effective learning systems. In this paper, we propose to combine the strengths of modal logics and neural networks by introducing Connectionist Modal ...
Artur S. d’Avila Garcez, Baldoni, Bose, Brewka, Broda, Broda, Castilho, Chagrov, Clark, Cybenco, Dov M. Gabbay, d’Avila Garcez, d’Avila Garcez, d’Avila Garcez, d’Avila Garcez, d’Avila Garcez, d’Avila Garcez, Fagin, Fitting, Fitting, Gabbay, Gabbay, Gelfond, Harel, Haykin, Huth, Lewis, Lloyd, Luís C. Lamb, Mitchell, Orgun, Rumelhart, Sakakibara, Shastri, Sun, Sun, Towell, Valiant, van Benthem, van Benthem, Zhou   +40 more
core   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source